Inhibitor Therapeutics, Inc.
INTI
$0.09
$0.0117.03%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.60% | -9.73% | -8.95% | -6.52% | -5.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.11% | -3.08% | -6.31% | 4.33% | 8.11% |
| Operating Income | 8.11% | 3.08% | 6.31% | -4.33% | -8.11% |
| Income Before Tax | 3.99% | -2.03% | 1.16% | -11.09% | -14.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.99% | -2.03% | 1.16% | -11.09% | -14.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.99% | -2.03% | 1.16% | -11.09% | -14.15% |
| EBIT | 8.11% | 3.08% | 6.31% | -4.33% | -8.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 4.50% | -1.57% | 1.55% | -11.17% | -13.64% |
| Normalized Basic EPS | 4.76% | -1.67% | 1.64% | -11.61% | -15.60% |
| EPS Diluted | 4.50% | -1.57% | 1.55% | -11.17% | -13.64% |
| Normalized Diluted EPS | 4.76% | -1.67% | 1.64% | -11.61% | -15.60% |
| Average Basic Shares Outstanding | 0.22% | 0.15% | 0.14% | 0.15% | 0.16% |
| Average Diluted Shares Outstanding | 0.22% | 0.15% | 0.14% | 0.15% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |